Skip to main menu Skip to main content Skip to footer

Francis Price, MD

Francis Price, MD

Ophthalmologist

Ophthalmologist in Indianapolis

Many of our patients at Price Vision Group are unaware that the eye doctor performing their eye exam is one of the premier ophthalmologists and LASIK specialists in the world. Indianapolis patients of Dr. Francis Price Jr. know him as a caring and gifted doctor who prioritizes their eye health and vision. But the numerous patients and physicians who travel great distances to benefit from his expertise know him as one of the top corneal specialists in the field.

Education and Experience

Dr. Price was born and raised on the south side of Indianapolis. Prior to his distinguished career in ophthalmology, Dr. Price graduated Phi Beta Kappa from the University of Notre Dame. He earned his medical degree from Indiana University Medical School, where he also completed his residency in ophthalmology. He completed a prestigious fellowship in corneal and external eye disease at Tulane University. He earned board-certification in ophthalmology, and established Price Vision Group more than 30 years ago.

Dr. Price established a nationally ranked cornea fellowship program here in Indianapolis that provides exceptional training to the next generation of cornea surgeons. The first laser vision correction procedure in Indiana was performed at Price Vision Group. He has played a key role in advancing LASIK by working directly with the American Society of Cataract & Refractive Surgeons and the American Academy of Ophthalmology

Personal

Dr. Price, The Person

If he wasn’t an ophthalmologist, Dr. Price says that he might choose to be a guide or tracker as his occupation because he loves nature. He would enjoy helping others get the same enjoyment that he does from hiking and canoeing. He also enjoys growing things and gardening, so perhaps a farmer would be his other occupation.

During his free time, Dr. Price enjoys traveling. Dr. Price and his wife usually make it a family affair and include their children and grandchildren. They especially enjoy canoeing the Canadian boundary waters.

A word from our patients

What Our Patients Are Saying About Dr. Price

He is the corneal expert. You look at the statistics of his results and it just all fits together. Dr. Price changed my life.

Katie Stam Irk, LASIK patient

Miss America 2009

I traveled all the way from California to have Dr. Price perform DMEK on both of my eyes due to Fuchs Dystrophy. He saved my career and I really appreciate Dr. Price’s great work.

Mark, DMEK patient

Orchestral Musician

Thanks to Dr. Price I can see everything around me and I feel better about coming to work. You have really made a big change in my life.

Edward, Cataract patient

Dentist

Read more about Dr. Price

Official CV

Education

Fellowship

Cornea and External Disease
Tulane University

Residency

Department of Ophthalmology
Indiana University

Internship

Methodist Hospital

Doctorate of Medicine

Indiana University

Bachelor of Science

University of Notre Dame

Recognition

Honors and Awards

  • Thomas C. Hasbrook Award – Bosma Visionary Opportunities Foundation (2017)
  • Life Achievement Honor Award – American Academy of Ophthalmology (2016)
  • Celebrating Catholic School Values Community Service Award (2015)
  • Asia Cornea Society Medalist (2014)
  • Barraquer Award for significant contributions in refractive surgery (2011)
  • Santa Caterina d’Oro da Siena award for excellence in medical research (2011)
  • Senior Achievement Award – American Academy of Ophthalmology (2009)
  • Health Care Heroes award, Indianapolis Business Journal (2008)
  • Albert D. Frost Memorial Lectureship, Ohio State University (2007)
  • Melvin Jones Fellow Award, Lions International Foundation (2007)
  • Silver Recognition Award, Indiana Academy of Ophthalmology (2006)
  • Vision Award, the Corneal Dystrophy Foundation (2006)
  • Person of Vision, Prevent Blindness Indiana (2006)
  • Indiana Hero, Indiana Pacers (2006)

Research

Publications

Clinical Trials

Research Studies

  • A multicenter clinical evaluation of the EVO/EVO+ Visian® Implantable Collamer® Lens. Staar Surgical, 2020/Active.
  • Post-approval study of the Visian® Toric Implantable Collamer® Lens. Staar Surgical, 2020/Active.
  • Prospective randomized study to determine whether use of Rhopressa™ can ammeliorate corneal edema associated with Fuchs dystrophy. Cornea Research Foundation of America, 2019/Active.
  • Effect of Xen implantation on the aqueous humor proteome. Cornea Research Foundation of America, 2019/Active.
  • Prospective randomized study to determine whether use of Rhopressa™ accelerates corneal clearing after removal of Descemet membrane for treatment of Fuchs dystrophy, Cornea Research Foundation of America/Price Vision Group, 2019/Active
  • Randomized Comparison of Standard vs Accelerated Corneal Cross Linking for Treatment of Progressive Keratoconus or Ectasia, Cornea Research Foundation of America/Price Vision Group, 2019/Active
  • A randomized, double-masked, placebo-controlled study of the safety of Amphotericin 0.255 μg/mL in Optisol-GS, Price Vision Group/Cornea Research Foundation of America, 2019/2019
  • Sub-Investigator. A multi-center, double-masked, randomized, placebo-controlled study of the efficacy and safety of HY02 ointment in subjects with inflamed Meibomian gland dysfunction. Hovione Scientia, 2019/Active.
  • Principal Investigator.A Phase 3, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of AGN-190584 in Participants with Presbyopia, Allergan, 2019/Active.
  • Co-Investigator.Phase 3, double-masked, randomized, controlled study of KPI-121 0.25% Ophthalmic suspension compared to vehicle in subjects with dry eye disease (Stride 3), Kala, 2018/Active
  • Principal Investigator. Effect of TrueTear use on anterior corneal surface imaging quality. Price Vision Group. 2018/2019.
  • Principal Investigator. Comparison of the aqueous humor in eyes undergoing routine cataract surgery vs. eyes having a transplant to treat Fuchs dystrophy vs. eyes having a regraft for cornea transplant failure. Cornea Research Foundation of America. 2018/Active.
  • Co-Investigator. Genetic susceptibility to contact lens related microbial keratitis. University Hospitals Cleveland Medical Center, 2018/Active.
  • Principal Investigator. Evaluation of keratoplasty outcomes. Cornea Research Foundation of America 2018/Active.
  • Principal Investigator. Retrospective study of treatments for keratoconus or ectasia. Cornea Research Foundation of America. 2017/Active.
  • Investigator, Artisan Aphakia Lens for the Correction of Aphakic in Adults, Ophtec, USA, 2017/Active
  • Co-Investigator. Discovery approach to ocular hypertension. National Institutes of Health, 2017/Active.
  • Principal Investigator. Randomized, double-masked, placebo-controlled evaluation of netarsudil for prevention of corticosteroid-induced intraocular pressure elevation. Cornea Research Foundation of America 2017/2019.
  • Sub-Investigator. A double-masked, randomized, multi-center Phase 2 study to evaluate the efficacy and safety of LacripepTM in subjects with dry eye associated with primary Sjogren’s syndrome. TearSolutions, Inc. 2017/2018.
  • Principal Investigator. Survey after crosslinking. Cornea Research Foundation of America 2017.
  • Principal Investigator, Evaluation of a camera attachment on a surgical microscope for cataract, anterior segment, cornea, and glaucoma surgery. Haag-Streit 2016/Active.
  • Principal Investigator, Characterization of the aqueous humor proteome before and after micropulse laser treatment for intraocular pressure reduction. Cornea Research Foundation of America 2016/2017.
  • Principal Investigator, A Phase 2, Multicenter, Double-masked, Randomized, Vehicle-Controlled, Study of the Concurrent Use of AGN-190584 and AGN-199201 in Patients with Presbyopia. Allergan 2016/2018.
  • Sub-Investigator, A Phase 3, double-masked, randomized, controlled study of KPI-121 0.25% ophthalmic suspension compared to vehicle in subjects with dry eye disease. Kala Pharmaceuticals 2016/2018.
  • Principal Investigator, Color vision before and after Descemet membrane endothelial keratoplasty (DMEK) compared with age-matched controls. Cornea Research Foundation of America 2015/2016.

  • Principal Investigator, A multi-center, open-label, parallel-arm, randomized, dose-ranging study of ENV515 (travoprost) intracameral implant in subjects with bilateral ocular hypertension or early primary open-angle glaucoma. Envisia Therapeutics Inc. 2015.
  • Principal Investigator, A Phase III double-masked, randomized, controlled trial of KPI-121 in postsurgical inflammation. Kala Pharmaceuticals, Inc. 2014/2015.
  • Principal Investigator. Randomized comparison of the use vs. non-use of mitomycin C in combination with epithelial removal and Descemet membrane endothelial keratoplasty. Cornea Research Foundation of America 2014/2015.
  • Principal Investigator, Safety and effectiveness of the CustomFlex artificial iris prosthesis for the treatment of iris defects. Clinical Research Consultants, Inc. 2013/2018.
  • Sub-investigator, A historically-controlled Phase II/III study to evaluate efficacy and safety of Kedrion human plasminogen eye drop preparation in patients diagnosed with ligneous conjunctivitis. Kedrion 2013/Active.
  • Principal Investigator A multi-center, randomized, placebo-controlled evaluation of the safety and efficacy of the KXL system with VibeX (riboflavin ophthalmic solution) for corneal collagen cross-linking in eyes with keratoconus. Protocol KXL-005. Avedro 2013/2017.
  • Principal Investigator, Evaluation of a camera attachment on a surgical microscope for cataract, anterior segment, cornea, and glaucoma surgery. Haag-Streit 2013/2015.
  • Principal Investigator. Prospective, randomized comparison of corticosteroid dosing regimens following endothelial keratoplasty. Cornea Research Foundation of America 2013/2015.
  • Principal Investigator. Kaneka TrimotionTM Injector Clinical Trial. Kaneka 2013.
  • Principal Investigator. Prospective study of the incidence of graft rejection episodes and intraocular pressure elevation in the second year after Descemet membrane endothelial keratoplasty. Cornea Research Foundation of America 2012/2016.
  • Principal Investigator. A multi-center, randomized, placebo-controlled evaluation of the safety and efficacy of the KXL system with VibeX (riboflavin ophthalmic solution) for corneal collagen cross-linking in eyes with keratoconus. Protocol KXL-002. Avedro 2012/2017.
  • Principal Investigator. A prospective, double-masked, placebo controlled comparison of topical 0.15% ganciclovir gel (Zirgan) versus 0.3% hypromellose gel (Genteal gel; placebo) for the treatment of adenovirus conjunctivitis. Lifelong Vision Foundation 2011/2013.
  • Principal Investigator. Evaluation of the Epiglare tester for the measurement of glare-induced changes in best spectacle corrected visual acuity in subjects with and without cataracts. Epico LLC 2011/2012.
  • Principal Investigator. Comparison of two corticosteroid-dosing regimens for prevention of corneal transplant rejection episodes after Descemet’s membrane endothelial keratoplasty. Cornea Research Foundation of America 2011/2013.
  • Principal Investigator. Characterization of the protein content of aqueous humor as related to cornea transplant survival. Cornea Research Foundation of America 2011/2015.
  • Principal Investigator. A Comparison of Three Endothelial Microscopy Techniques. Cornea Research Foundation of America 2011.
  • Principal Investigator. Efficacy and Safety of Bromfenac Ophthalmic Solution vs. Placebo for The Treatment of Ocular Inflammation and Pain Associated with Cataract Surgery. ISTA 2011.
  • Principal Investigator. A randomized, prospective, double masked clinical trial of Life 4°C vs. Optisol GS corneal storage media. Numedis, Inc. 2011/2012.
  • Principal Investigator. A multi-center, double-masked, randomized, vehicle-controlled, parallel-group study to evaluate the safety and efficacy of 0.005% and 0.010% aqueous cyclosporine ophthalmic solutions administered twice daily for at least two weeks prior to and six months after LASIK surgery in reducing post-LASIK corneal hypoesthesia. Allergan 2010/2011.
  • Principal Investigator. Evaluation of Corneal Cross Linking for Treatment of Corneal Edema. Cornea Research Foundation of America. 2010/2011.

  • Principal Investigator. Survey study comparing contact lenses and LASIK for vision correction. Cornea Research Foundation of America 2010/2016.
  • Principal Investigator. Evaluation of two Riboflavin Dosing Regimens for Corneal Collagen Cross-Linking in Eyes with Progressive Keratoconus or Ectasia. Cornea Research Foundation of America 2010/2017.
  • Principal Investigator. Clinical Protocol for the Treatment of Corticosteroid Induced Intra-ocular Pressure Increases After Corneal Transplantation. Cornea Research Foundation of America 2009/2010.
  • Principal Investigator. A Prospective Evaluation of Treatment Duration of the UVXTM System for treating infectious keratitis. Cornea Research Foundation of America 2009/2013.
  • Principal Investigator A prospective multi-center clinical study to evaluate the safety and effectiveness of the light adjustable lens (LAL) in subjects undergoing cataract extraction. Calhoun Vision, Inc. 2009/2013.
  • Principal Investigator A Multi-Center, Parallel-Group, Double-Masked, Randomized, Placebo-Controlled Study of the Effects of diquafosol tetrasodium Ophthalmic Solution, 2% in Subjects with Dry Eye Disease and a Central Corneal Staining Score of 3 (NEI Scale). Inspire Pharmaceuticals, Inc. 2009/2010.
  • Principal Investigator Efficacy and safety of bromfenac ophthalmic solution QD vs. placebo QD for treatment of ocular inflammation and pain associated with cataract surgery. ISTA Pharmaceuticals, Inc. 2009.
  • Principal Investigator A prospective study of Staar ICL metrics. Cornea Research Foundation of America – 2008/2009.
  • Principal Investigator. A randomized, observer-masked, parallel-group, multicenter trial evaluating the ocular penetration of 1.5% levofloxacin ophthalmic solution and 0.5% moxifloxacin ophthalmic solution in subjects undergoing corneal transplant surgery. Vistakon Pharmaceuticals, LLC – 2008/2009.
  • Principal Investigator. Open-enrollment, prospective study of endothelial keratoplasty outcomes. Cornea Research Foundation of America – 2008/Active.
  • Principal Investigator. Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes with Progressive Keratoconus. Peschke Meditrade GmbH – 2008/2011.
  • Principal Investigator Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes with Corneal Ectasia after Refractive Surgery. Peschke Meditrade GmbH – 2008/2011.
  • Principal Investigator Characterization of the protein content of aqueous humor. Cornea Research Foundation of America 2008/2013.
  • Principal Investigator Surveillance of resistance to formulations of antimicrobials in cultures of the eye. Allergan, Inc. 2007/2008.
  • Principal Investigator A Multi Center, Double Masked, Randomized Parallel Group Study Evaluating the Safety and Efficacy of a New Formulation of Ketorolac Tromethamine 0.45% Ophthalmic Solution Compared with Vehicle Administered Preoperatively and Twice-Daily Postoperatively for Two Weeks for the Treatment of Anterior Segment Inflammation, Pain, and Inhibition of Surgically Induced Miosis Following Cataract Extraction with Posterior Chamber Intraocular Lens (IOL) Implantation. Allergan, Inc. 2007/2008.
  • Principal Investigator A prospective, randomized, multicenter center study evaluating the use of intraocular dexamethasone in conjunction with Descemet’s stripping and endothelial keratoplasty, a type of cornea transplant. Cornea Research Foundation of America and Ophthalmic Consultants of Long Island – 2007/2009.
  • Principal Investigator Intraocular Pressure after Descemet’s stripping endothelial keratoplasty as measured by contour matching tonometry and applanation tonometry. Cornea Research Foundation of America – 2007.
  • Principal Investigator. Clinical evaluation of the safety and effectiveness of the Veriflex anterior chamber phakic IOL for the correction of myopia. Advanced Medical Optics – 2007/2016.
  • Principal Investigator. A multi-center, placebo-controlled, randomized, parallel-group, dose-ranging study to assess the efficacy and safety of LX201 implantation for the prevention of corneal allograft rejection episodes or graft failure in subjects who have experienced one or more rejection episodes following penetrating keratoplasty. Lux Biosciences – 2007/2010.
  • Principal Investigator. A multi-center, placebo-controlled, randomized, parallel-group, dose-ranging study to assess the efficacy and safety of LX201 for the prevention of allograft rejection episodes and graft failure following penetrating keratoplasty with LX201 implantation in subjects who are at increased immunological risk. Lux Biosciences – 2007/2010.
  • Principal Investigator. A prospective, multi-center feasibility trial to evaluate the safety and effectiveness of the IntraLase FS laser used to harvest donor tissue for Descemet’s stripping with endothelial keratoplasty. IntraLase Corp. – 2007/2008.
  • Principal Investigator. A Randomized Evaluation of Two Surgical Kits: Gatifloxacin, Ketorolac LS, and Pred Forte Compared with Moxifloxacin, Nepafenac, and EconoPred in Patients Undergoing Cataract Surgery. William Trattler, MD – 2006.
  • Principal Investigator. Comparative Study of Corneal Transplant Survival and Endothelial Cell Loss following Descemet Stripping Automated Endothelial Keratoplasty vs. Penetrating Keratoplasty. Case Vision Research Coordinating Center – 2006/2010.
  • Principal Investigator. FECD Genetics Multi-Center Study. Case Vision Research Coordinating Center – 2006/2010.
  • Principal Investigator. A prospective, randomized, single center study evaluating use of surgeon- and eye bank-prepared donor tissue for Descemet’s stripping and endothelial keratoplasty, a type of cornea transplant. Protocol 2005-10. Cornea Research Foundation of America and the North Carolina Eye Bank, Inc. – 2006/2007.
  • Principal Investigator. A prospective, multi-center feasibility trial to evaluate the IntraLase FS laser used for penetrating keratoplasty. Protocol FMTO-007-ITK.  IntraLase Corp. – 2005/2006.
  • Principal Investigator. A multi-center, double-masked, randomized, placebo controlled, evaluation of the onset and duration of action of R89674 0.25% ophthalmic solution in the conjunctival allergen challenge (CAC) model of acute allergic conjunctivitis. Protocol 05-003-11.  Vistakon Pharmaceuticals, LLC – 2005/2006.
  • Principal Investigator. A study to determine whether early corneal protein changes associated with keratoconus can be identified through 2-dimensional gel electrophoresis and mass spectrometric analysis of human tear samples. Protocol: K-10-03-001.  Cornea Research Foundation of America – 2004/2006.

  • Principal Investigator Randomized, controlled, multicenter comparative trial to evaluate the SOLX Gold Shunt for the reduction of intraocular pressure (IOP) in glaucomatous eyes following failed medical and conventional surgical treatments. Protocol SLX53.  SOLX – 2005/2013.
  • Principal Investigator. A masked comparison of Acular LS plus steroid versus steroid alone for the prevention of macular leakage in cataract patients. John Wittpenn, MD – 2005/2007.
  • Principal Investigator. Comparison of healing response of the corneal wound created by blade or femtosecond laser, in presence of implanted hydrogel sponge. Protocol 2902. CooperVision – 2005.
  • Principal Investigator. A prospective, randomized, single-center clinical trial to evaluate the use of orbital seal sunglasses after LASIK. Protocol 2004-20.  Panoptx – 2004/2005.
  • Principal Investigator. A prospective, randomized, multi-center clinical comparison of fellow eyes undergoing LASIK with either a mechanical keratome or IntraLase FS laser. Protocol PRIM-016-CST.  IntraLase Corp – 2004/2005.
  • Principal Investigator. A prospective, single-center feasibility trial to evaluate the safety and effectiveness of the IntraLase FS laser used for corneal endostromal tissue harvesting. Protocol FMTO-006-ITK.  IntraLase Corp – 2004/2005.
  • Principal Investigator. Clinical study of implantation of a UV-absorbing acrylic posterior chamber intraocular lens. Protocol 2003-A101.  Hoya Holdings, Inc. – 2004/2008.
  • Principal Investigator. A study to determine if RestasisTM (cyclosporin 0.05% ophthalmic solution) is effective, either alone or in combination with pulsed dosing of corticosteroids, for prevention of graft rejection episodes after corneal transplantation. Protocol R-09-03-002.  Price Vision Group – 2003/2005.
  • Principal Investigator. A prospective, randomized, double-masked study to evaluate whether pre-operative dosing with Acular LS is effective for maintaining pupil dilation and for mitigating pain and inflammation during and after cataract surgery. Protocol A-09-03-001.  Price Vision Group – 2003/2004.
  • Principal Investigator. A Study to Compare the Effect of Gatifloxacin 0.3% and Moxifloxacin 0.5% Ophthalmic Solutions on Corneal Epithelial cell health following two dosing regimens. Protocol 08-03-001.  Price Vision Group – 2003.
  • Principal Investigator. A comparison of the duration of IOP control with travopost, bimatoprost, and latanoprost in patients with glaucoma and ocular hypertension: a multicenter, randomized, masked-evaluator, parallel group study. Protocol 03-005-03.  Ophthalmic Research Associates – 2003.
  • Principal Investigator. To evaluate the effect of gatifloxacin 0.3% ophthalmic solution on corneal endothelial cell counts in two subpopulations: non-surgical, normal healthy volunteers and healthy volunteers scheduled to undergo standard cataract surgery.  Protocol PIND-GATI-004.  Allergan – 2003.
  • Principal Investigator. A comparative study of olopatadine QD versus vehicle in patients with seasonal allergic conjunctivitis or rhinoconjunctivitis. Protocol C-02-67.  Alcon – 2003.
  • Principal Investigator. Phase II study: a multi-center, double-masked, randomized, vehicle-controlled, parallel group study to evaluate the safety and efficacy of testosterone (0.01%, 0.03% and 0.1%) ophthalmic solution administered twice daily for up to 6 months in patients with Meibomian gland dysfunction (MGD). Allergan 2003/2003.
  • Medical Monitor and Principal Investigator. Multicenter Clinical Study of the Ophthec Model 311 Iris Reconstruction Lens. FDA IDE Number: G020127 and G020127/A001.  OPHTEC USA, Inc. – 2002/
  • Principal Investigator. Multicenter Clinical Study of the OCULAID Endocapsular Tension Ring (CTR) and OPERAID Tension Ring Inserter. FDA IDE Number: G010064.  Protocol CTR 275/276. OPHTEC USA, Inc.– 2001/2004
  • Principal Investigator. A multi-center, randomized, double-masked, vehicle-controlled, parallel-group study evaluating the safety and analgesic efficacy of Ketorolac Tromethamine 0.4% ophthalmic solution in post photorefractive keratectomy patients. Protocol 191578-003. Allergan – 2001/2002
  • Principal Investigator. A prospective, masked study comparing preservative-free Acular to vehicle for analgesic efficacy after LASIK. Allergan – 2000/2001.
  • Principal Investigator – A prospective, masked study to compare the effectiveness of antibiotics to penetrate into the eye. Allergan – 2000/2001.

  • Principal Investigator. The Cornea Donor Study: A prospective cohort study to determine whether the graft-failure rate over a 5-year follow-up period is equivalent with corneal tissue from donors older than 65 years of age compared with that from younger donors. Two other specific objectives also evaluated.  Protocol Version 1.0- Jaeb Center for Health Research – 1999/2012.
  • Co-Investigator. Clinical evaluation of a new method to remove the Landec Punctal Occluder. Protocol C-98-15. Alcon Laboratories, Inc. – 1999
  • Principal Investigator. US Clinical Study of the Artisan Myopia Lens for the Correction of High Myopia in Phakic Eyes. Ophtec USA, Inc. – 1998/2007
  • Principal Investigator and Sponsor. A Phase III Prospective Controlled Clinical Trial to Investigate the Ability to Decrease the Rate of Over-correction without Increasing the Rate of Retreatment due to Under-correction with Laser in Situ Keratomileusis. EXKM-802.   Protocol 980968. Corneal Consultants of Indiana – 1998-9/2000
  • Principal Investigator. Clinical study of the implantable contact lens for patients with moderate to high hyperopia. Protocol 980363. STAAR® Surgical – 1998-4/2000
  • Principal Investigator. A Phase III study of MDX-RA compared with placebo administered in
  • patients undergoing phacoemulsification or planned extracapsular extraction for cataract. Protocol CL-SEC014.  – Medarex, Inc. 1998-4/2000
  • Principal Investigator. A Multi-Center Prospective Clinical Study to Evaluate the Use of the LADARVision Excimer Laser System in LASIK Correction of Hyperopia and Astigmatism. Protocol 7201-0022. Autonomous Technologies Corporation – 1998/2000
  • Principal Investigator. A Multi-Center Prospective Clinical Study to Evaluate the Use of LADARVision System in Correction of Hyperopia and Astigmatism. Protocol 7201-0010. Autonomous Technologies Corporation – 1998/1999
  • Principal Investigator and Sponsor. A Phase III prospective randomized controlled clinical trial to investigate the use versus non-use of topical corticosteroids on the stability of the manifest refraction after the surgical correction of myopia and astigmatism with laser in situ keratomileusis. Protocol EXKM-801. Corneal Consultants of Indiana – 1997/2000
  • Principal Investigator and Sponsor. A Phase III prospective randomized controlled clinical trial to investigate the simultaneous versus sequential surgical correction of myopia and astigmatism with laser in situ keratomileusis. Protocol EXKM-800. Corneal Consultants of Indiana – 1996

  • Co-Investigator for a Phase III prospective multi center clinical trial to evaluate the safety of the Chiron Technolas™ Keracor™ 116 excimer laser for the correction of mild myopia and astigmatism in fellow eyes of subject initially treated under protocol EXCM-650-MYO. Protocol EXCM-651-FEL. Chiron Vision Corp. – 1995
  • Co-Investigator for a Phase III prospective multi center clinical trial to evaluate the safety and effectiveness of the Chiron Technolas™ 116 excimer laser for the correction of mild myopia. Protocol EXCM-650-MYO. Chiron Vision Corp. – 1995
  • Co-Investigator for a protocol for the retreatment of eyes with under-corrected refractive error following photorefractive keratectomy with the Chiron Technolas™ Keracor™ 116 excimer laser. Protocol EXCM-622-RET. Chiron Vision Corp. – 1995
  • Co-Investigator for a clinical trial to evaluate the use of the Chiron Technolas Keracor™ 116 excimer laser for the correction of residual myopia or of untreated fellow eyes in patients treated with the Taunton 2015 excimer laser. Protocol EXCM-620-TET. Chiron Vision Corp. – 1995
  • Principal Investigator for the analgesic efficacy of ketorolac tromethamine 0.5% diclofenac sodium 0.1% when used following bilateral radial keratotomy. Allergan Pharmaceuticals – 1995
  • Principal Investigator for a Phase II prospective randomized controlled multi center clinical trial to compare surgical correction of myopia with excimer laser photorefractive keratectomy versus laser in situ keratomileusis. Protocol EXKM-603-MYO. Chiron Vision Corp.- 1995
  • Principal Investigator for a Phase II multi center clinical trial to evaluate the use of the excimer laser for the treatment of superficial corneal opacities. Protocol EXCM-615-PTK. Chiron Vision Corp. – 1994
  • Principal Investigator for a retrospective ALK study. Submitting 100 patients. Refractive Services Agency – 1994
  • Principal Investigator for the analgesic efficacy and safety of KETOROLAC non-preserved ophthalmic solution in subjects undergoing radial keratotomy. Study KETO-105-8718 Allergan – 1994/1995
  • Principal Investigator for a randomized open clinical trial for the evaluation of corneal tissue levels following topical dosing with OCUFLOX solution. Allergan – 1994
  • Principal Investigator for an adjunctive therapy with Galardin™ matrix metalloproteinase inhibitor (GM 6001) in patients with corneal ulcers caused by infection. Galardin – 1993/1994
  • Principal Investigator for a retrospective multi center clinical study to evaluate the clinical outcome of keratorefractive surgery for the correction of myopia and astigmatism. Chiron IntraOptics -1992/1993
  • Principal Investigator for a prospective multi center clinical trial to evaluate keratorefractive surgery for the correction of myopia and astigmatism. Chiron IntraOptics – 1992/1993
  • Principal Investigator for a prospective multi center clinical trial to evaluate keratorefractive surgery for the correction of myopia. Chiron IntraOptics – 1992/1993
  • Principal Investigator for a randomized open clinical trial for the evaluation of corneal tissue levels following topical dosing with CILOXAN solution. Alcon Laboratories – 1992/1993
  • Principal Investigator for clinical trials to evaluate the excimer laser used for photorefractive keratectomy (PRK), Phase III ‑ VISX Incorporated – 1992-1994
  • Principal Investigator for clinical trials to evaluate the excimer laser for use in phototherapeutic corneal surgery (PTK), Phase IIB – VISX Incorporated – 1992-1995
  • Principal Investigator for a randomized, double‑masked clinical trial to assess the safety and comparative efficacy of three concentrations of Sandimmune ophthalmic ointment versus placebo in patients with keratoconjunctivitis sicca. ‑ Sandoz Research Institute – 1991
  • Principal Investigator for a clinical trial to evaluate the handling, fit, retention, and comfort of the Chiron corneal shield in postoperative patients. ‑ Chiron Ophthalmics, Inc.- 1991
  • Principal Investigator for intraocular pressure raising potential of Rimexolone in high steroid responders. ‑ Alcon Laboratories – 1991/1992
  • Principal Investigator for a randomized controlled multi center study to evaluate the effect of collagen shields on corneal epithelialization following pene­trating keratoplasty. Chiron Ophthalmics, Inc. – 1991
  • Principal Investigator for clinical trials to evaluate the safety and efficacy of Sandimmune 2% Ophthalmic Ointment in the prevention of corneal graft rejection following “high risk” keratoplasty. Sandoz Research Institute, East Hanover, NJ – 1989-1992
  • Principal Investigator for placebo‑controlled study to evaluate the safety and efficacy of Fibronectin ophthalmic solution in patients with keratoconjunctivitis sicca. Chiron Ophthalmics, Inc., Irvine, CA – 1988-1990
  • Principal Investigator for clinical evaluation of corneal preser­vation media containing human Epidermal Growth Factor and insulin. Chiron Ophthalmics, Inc., Irvine, CA – 1988-1990
  • Principal Investigator for the clinical evaluation of a hydrogel intracorneal implant (Kerato‑Gel) for the correction of aphakia; Allergan Medical Optics, Santa Ana, CA – 1988
  • Principal Investigator for the clinical evaluation of a hydrogel intracorneal implant (Kerato‑Gel) for the correction of myopia; Allergan Medical Optics, Santa Ana, CA – 1988
  • Principal Investigator for Fibronectin used in the treatment of recurrent corneal erosions; Chiron Ophthalmics, Inc., Irvine, CA 1987/1988
  • Principal Investigator for Fibronectin used in the treatment of persistent corneal defects; Chiron Ophthalmics, Inc., Irvine, CA 1987/1988
  • Principal Investigator for human Epidermal Growth Factor to promote healing of penetrating keratoplasties; Chiron Ophthalmics, Inc. – 1986/1987
  • Principal Investigator for human Epidermal Growth Factor to promote healing of non‑healing corneal defects; Chiron Ophthalmics, Inc., Irvine, CA – 1986/1987
  • Investigator for BKS‑1000 ‑ Non-Freeze Keratomileusis; American Medical Optics, Irvine, CA – 1986

Schedule a Visit

Ready to Schedule Your Visit?

Schedule your appointment today.

Our Doctors

⇧